BQL Healthcare USA Inc. is a US-owned technology company commercializing the Dual-flow Lab-on-a-Chip platform developed at the University of Cincinnati. Our products combine laboratory-grade sensitivity with the simplicity of a paper test and the accessibility of a smartphone.
Three principal investigators with proven industrialization, microfluidics, and clinical immunoassay expertise.
Cincinnati for research and laboratory infrastructure. Fort Lauderdale for corporate operations.
Cincinnati, OH
Fort Lauderdale, FL
Sell handheld readers at cost to lower entry barriers in resource-limited settings, while generating high-margin recurring revenue from single-use diagnostic cartridges.
Provide anonymized diagnostic data to public health agencies and integrate with telehealth providers, creating a longitudinal feedback loop between field tests and care providers.
An aggressive but staged path: non-dilutive funding first, regulatory clearance second, deployment third.
Pursuing Bill Gates Foundation Grand Challenges, NIH SBIR Phase I, and Ohio TVSF programs.
Reagent stabilization for ≥12-month shelf life (10-37°C); scFv-HRP fusion antibody scale-up.
F programs.
FDA Q-Submission, Class II 510(k) or De Novo path, CLIA Waiver design.
LMIC field deployment via WHO/Pasteur/CDC channels; US clinical rollout via Razor & Blade model.
Next-generation In Vitro Diagnostics, built on dual-flow Lab-on-a-Chip technology licensed from the University of Cincinnati.
Products described on this site are in development. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. They are not yet available for sale.
© 2026 BQL Healthcare USA Inc. All rights reserved.